Infliximab in the treatment of patients with severe covid-19 (inflixcovid): protocol for a randomised, controlled, multicentre, open-label phase ii clinical study

HIGHLIGHTS

  • who: Sina M. Coldewey from the Department of Anaesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum, Jena, Germany have published the research work: Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): protocol for a randomised, controlled, multicentre, open-label phase II clinical study, in the Journal: (JOURNAL) of 11/06/2021
  • what: The overall aim of this randomised, controlled, multicentre, open-label phase II clinical trial is the improvement of the survival of patients with COVID-19 at high risk for severe disease by repurposing a clinically established and globally . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?